MYD88 L265P and CD79B Y196 are the two most common gain-of-function mutations in PCNSL, which are parts of toll-like receptors (TLR) and B-cell receptor (BCR) signaling pathways, respectively (10–12). This evidence concerns the gene CD79B and primary central nervous system lymphoma.